Factors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin

BMC Infectious Diseases

Eric Senneville⁴  Stephan Haulon²  Olivier Leroy¹  Michel Valette⁴  Massongo Massongo⁴  Cécile Rouyer⁴  Béatrice Sarraz-Bournet³  Piervito Delia²  Laurence Legout⁴ 

[1] Intensive Care and Infectious Diseases Unit, Dron Hospital of Tourcoing, Tourcoing, France;Department of Vascular Surgery, University Hospital of Lille, Lille, France;Department of Vascular Surgery, Dron Hospital of Tourcoing, Tourcoing, France;Infectious Diseases Department, Dron Hospital of Tourcoing, Rue du Président Coty, Tourcoing 59208, France

关键词: Rifampin;    Staphylococci;    Prosthesis infection;    Vascular graft infection;   

Others  :  1133973
DOI  :  10.1186/1471-2334-14-228

 received in 2013-10-08, accepted in 2014-03-12,  发布年份 2014

【 摘 要 】

Background

There exists considerable debate concerning management of prosthetic vascular graft infection (PVGI), especially in terms of antimicrobial treatment. This report studies factors associated with treatment failure in a cohort of patients with staphylococcal PVGI, along with the impact of rifampin (RIF).

Methods

All data on patients with PVGI between 2006 and 2010 were reviewed. Cure was defined as the absence of evidence of infection during the entire post-treatment follow-up for a minimum of one year. Failure was defined as any other outcome.

Results

84 patients (72 M/12 F, median age 64.5 ± 11 y) with diabetes mellitus (n = 25), obesity (n = 48), coronary artery disease (n = 48), renal failure (n = 24) or COPD (n = 22) were treated for PVGI (median follow-up was 470 ± 469 d). PVGI was primarily intracavitary (n = 47). Staphylococcus aureus (n = 65; including 17 methicillin-resistant S. aureus) and coagulase-negative Staphylocococcus (n = 22) were identified. Surgical treatment was performed in 71 patients. In univariate analysis, significant risk factors associated with failure were renal failure (p = 0.04), aortic aneurysm (p = 0.03), fever (p = 0.009), aneurysm disruption (p = 0.02), septic shock in the peri-operative period (p = 0.005) and antibiotic treatment containing RIF (p = 0.03). In multivariate analysis, 2 variables were independently associated with failure:septic shock [OR 4.98: CI 95% 1.45-16.99; p=0.01] and antibiotic containing rifampin [OR: 0.32: CI95% 0.10-0.96; p=0.04].

Conclusion

Results of the present study suggest that fever, septic shock and non-use of antibiotic treatment containing RIF are associated with poor outcome.

【 授权许可】

   
2014 Legout et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]FitzGerald SF, Kelly C, Humphreys H: Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus. J Antimicrob Chemother 2005, 56(6):996-999.
• [2]Yeager RA, McConnell DB, Sasaki TM, Vetto RM: Aortic and peripheral prosthetic graft infection: differential management and causes of mortality. Am J Surg 1985, 150(1):36-43.
• [3]Legout L, Sarraz-Bournet B, D’Elia PV, Devos P, Pasquet A, Caillaux M, Wallet F, Yazdanpanah Y, Senneville E, Haulon S, Leroy O: Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study. Clin Microbiol Infect 2012, 18(4):352-358.
• [4]Darouiche RO: Treatment of infections associated with surgical implants. N Engl J Med 2004, 350(14):1422-1429.
• [5]Gandelman G, Frishman WH, Wiese C, Green-Gastwirth V, Hong S, Aronow WS, Horowitz HW: Intravascular device infections: epidemiology, diagnosis, and management. Cardiol Rev 2007, 15(1):13-23.
• [6]Baddour LM, Bettmann MA, Bolger AF, Epstein AE, Ferrieri P, Gerber MA, Gewitz MH, Jacobs AK, Levison ME, Newburger JW, Pallasch TJ, Wilson WR, Baltimore RS, Falace DA, Shulman ST, Tani LY, Taubert KA: Nonvalvular cardiovascular device-related infections. Circulation 2003, 108(16):2015-2031.
• [7]Kieffer E, Gomes D, Chiche L, Fleron MH, Koskas F, Bahnini A: Allograft replacement for infrarenal aortic graft infection: early and late results in 179 patients. J Vasc Surg 2004, 39(5):1009-1017.
• [8]Gassel HJ, Klein I, Steger U, Kellersmann R, Hamelmann W, Franke S, Thiede A: Surgical management of prosthetic vascular graft infection: comparative retrospective analysis of 30 consecutive cases. Vasa 2002, 31(1):48-55.
• [9]Goeau-Brissonniere O, Mercier F, Nicolas MH, Bacourt F, Coggia M, Lebrault C, Pechère JC: Treatment of vascular graft infection by in situ replacement with a rifampin-bonded gelatin-sealed Dacron graft. J Vasc Surg 1994, 19(4):739-741.
• [10]Blanch M, Berjon J, Vila R, Simeon JM, Romera A, Riera S, Cairols MA: The management of aortic stent-graft infection: endograft removal versus conservative treatment. Ann Vasc Surg 2010, 24(4):554. e1-5
• [11]Mingoli A, Sapienza P, Feldhaus RJ, di Marzo L, Burchi C, Cavallaro A: Aortoiliofemoral bypass graft in young adults: long-term results in a series of sixty-eight patients. Surgery 1997, 121(6):646-653.
• [12]O’Connor S, Andrew P, Batt M, Becquemin JP: A systematic review and meta-analysis of treatments for aortic graft infection. J Vasc Surg 2006, 44(1):38-45.
• [13]Smith K, Perez A, Ramage G, Gemmell CG, Lang S: Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents 2009, 33(4):374-378.
• [14]Edmiston CE Jr, Goheen MP, Seabrook GR, Johnson CP, Lewis BD, Brown KR, Towne JB: Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg 2006, 192(3):344-354.
• [15]LaPlante KL, Woodmansee S: Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother 2009, 53(9):3880-3886.
• [16]Bayer AS, Lam K: Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis 1985, 151(1):157-165.
• [17]Riedel DJ, Weekes E, Forrest GN: Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52(7):2463-2467.
• [18]Faville RJ Jr, Zaske DE, Kaplan EL, Crossley K, Sabath LD, Quie PG: Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA 1978, 240(18):1963-1965.
• [19]Senneville E, Gaworowska D, Topolinski H, Devemy F, Nguyen S, Singer B, Beltrand E, Legout L, Caillaux M, Descamps D, Canonne JP, Yazdanpanah Y: Outcome of patients with diabetes with negative percutaneous bone biopsy performed for suspicion of osteomyelitis of the foot. Diabet Med 2012, 29(1):56-61.
• [20]Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998, 279(19):1537-1541.
• [21]Widmer AF, Gaechter A, Ochsner PE, Zimmerli W: Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 1992, 14(6):1251-1253.
• [22]Nguyen S, Pasquet A, Legout L, Beltrand E, Dubreuil L, Migaud H, Yazdanpanah Y, Senneville E: Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009, 15(12):1163-1169.
• [23]Legout L, D’Elia P, Devos P, Ettahar N, Sarraz-Bournet B, Haulon S, Senneville E, Leroy O: Risk factors for methicillin-resistant staphylococcal vascular graft infection in an 11-year cohort study. J Infect 2012, 64(4):441-444.
• [24]Roon AJ, Malone JM, Moore WS, Bean B, Campagna G: Bacteremic infectability: a function of vascular graft material and design. J Surg Res 1977, 22(5):489-498.
• [25]Malone JM, Moore WS, Campagna G, Bean B: Bacteremic infectability of vascular grafts: the influence of pseudointimal integrity and duration of graft function. Surgery 1975, 78(2):211-216.
• [26]The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20(7):1183-1197.
• [27]Celli BR, Snider GL, Heffner J, Tiep B, Ziment I, Make B, Braman S, Olsen G, Phillips Y: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995, 152:S77-S121.
• [28]Garrow JS, Webster J: Quetelet’s index (W/H2) as a measure of fatness. Int J Obes 1985, 9(2):147-153.
• [29]Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130(6):461-470.
• [30]Chalmers RT, Wolfe JH, Cheshire NJ, Stansby G, Nicolaides AN, Mansfield AO, Barrett SP: Improved management of infrainguinal bypass graft infection with methicillin-resistant Staphylococcus aureus. Br J Surg 1999, 86(11):1433-1436.
• [31]Saleem BR, Meerwaldt R, Tielliu IF, Verhoeven EL, van den Dungen JJ, Zeebregts CJ: Conservative treatment of vascular prosthetic graft infection is associated with high mortality. Am J Surg 2010, 200(1):47-52.
• [32]Mirzaie M, Schmitto JD, Tirilomis T, Fatehpur S, Liakopoulos OJ, Teucher N, Dörge H, Schöndube FA: Surgical management of vascular graft infection in severely ill patients by partial resection of the infected prosthesis. Eur J Vasc Endovasc Surg 2007, 33(5):610-613.
• [33]Reilly LM, Stoney RJ, Goldstone J, Ehrenfeld WK: Improved management of aortic graft infection: the influence of operation sequence and staging. J Vasc Surg 1987, 5(3):421-431.
• [34]Calligaro KD, Veith FJ, Schwartz ML, Savarese RP, DeLaurentis DA: Are gram-negative bacteria a contraindication to selective preservation of infected prosthetic arterial grafts? J Vasc Surg 1992, 16(3):337-345. discussion 45–6
• [35]Coselli JS, LeMaire SA, Conklin LD, Koksoy C, Schmittling ZC: Morbidity and mortality after extent II thoracoabdominal aortic aneurysm repair. Ann Thorac Surg 2002, 73(4):1107-1115. discussion 15–6
• [36]Senneville E, Joulie D, Legout L, Valette M, Dezèque H, Beltrand E, Roselé B, d'Escrivan T, Loïez C, Caillaux M, Yazdanpanah Y, Maynou C, Migaud H: Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011, 53(4):334-340.
• [37]Sendi P, Graber P, Zimmerli W: Risk factors associated with acute hip prosthetic joint infections and outcome of treatment with a rifampin-based regimen. Acta Orthop 2008, 79(3):454. author reply 5
• [38]Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG: Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008, 168(8):805-819.
• [39]Leroy O, Meybeck A, Sarraz-Bournet B, D’Elia P, Legout L: Vascular graft infections. Curr Opin Infect Dis 2012, 25(2):154-158.